GSK launches $2.5 billion buyback, lifts sales target after stellar fourth quarter
GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...
FiercePharma7d
With Blenrep's revival, GSK dials up long-term sales goal—again—despite RSV vaccine woes
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
GlobalData on MSN7d
GSK stays optimistic on vaccines amidst US and China woes
While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...
J.P. Morgan Sticks to Its Sell Rating for GlaxoSmithKline (GSK)
J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.
TipRanks on MSN1d
GSK Executives Involved in Share Vesting and Sales
GSK announced several transactions involving the vesting and sale of ordinary shares under its Performance Share Plan and Deferred Investment Award Programme. The transactions involve key executives, ...
The Washington Post7d
Glaxo: Q4 Earnings Snapshot
BRENTFORD, Britain — BRENTFORD, Britain — GSK plc (GSK) on Wednesday reported fourth-quarter earnings of $530.5 million. On a per-share basis, the Brentford, Britain-based company said it had ...
BioPharma Dive7d
GSK, Pfizer sales of RSV shots slow as vaccination rates ebb
Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their ...